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Background: Breast cancer is the most common type of cancer and the second leading cause of cancer-death
among women in Poland. The known high-risk mutations account for 25% of familial aggregation cases and 5% of
total breast cancer predisposition. Genome-wide association studies have identified a number of common low-
penetrance genetic variants, but their contribution to disease risk differs between populations.
Methods: To verify selected associations with breast cancer susceptibility among Polish women, the replication
study was performed, included 1424 women with breast cancer and 1788 healthy persons. Sixteen single-
nucleotide polymorphisms (SNPs) were analyzed using TaqMan SNP Genotyping Assays. Allele frequency differences
were tested using chi2-test implemented in PLINK v1.07 and Cochran-Armitage trend test was performed using R
software.
Results: Significant differences (Bonferroni corrected p-valuecor ≤ 0.0197) in the frequency of alleles distribution
between all cancer and control subjects were observed for four (rs2736098, rs13281615, rs1219648, rs2981582) out
of 16 SNPs. The same result was obtained for group of patients without high-risk BRCA1/2 mutations. The rs1219648
(p-valuecor ≤ 6.73E-03) and rs2981582 (p-valuecor ≤ 6.48E-03) SNPs showed significant association with both familial
and sporadic cancers. Additionally, rs2736098 (p-valuecor ≤ 0.0234) was associated with only sporadic cancers; also
in group without carriers of high-risk mutation. All these associations revealed their significance also in Cochran-
Armitage trend test. Opposite to other SNPs, rs2736098 was associated with a decreased risk of breast cancer.
Conclusion: The association of four known susceptibility SNPs, representing three individual loci, with breast cancer
risk in Polish women was confirmed. One of them (rs2736098) seems to be specific for the Polish population. Due
to the population differences in allele frequencies, identification of general genetic risk factors requires sets of
association studies conducted on different populations.
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Breast cancer is the most commonly occurring cancer
among women worldwide [1]. In Poland it accounts for
over 20% of all malignant tumors and is the second most
frequent cause of cancer-related death [2]. Although the
majority of breast cancer cases are sporadic, a noticeable
portion results from highly penetrating inherited muta-
tion in susceptibility genes and family history remains* Correspondence: hennige@coi.waw.pl
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reproduction in any medium, provided the orthe best predictor of their individual risk [3]. Among
known predisposition genes, deleterious mutations in
BRCA1 and BRCA2 confer the strongest effect on dis-
ease susceptibility and are associated with a lifetime risk
of breast cancer of up to 85% for such mutation carriers
[4,5].
Even though the impact of high-risk gene mutations is
noticeable, they account for only about 25% of the famil-
ial risk and less than 5% of total breast cancer predispos-
ition, as their frequencies in general population are very
low [6]. It is suggested that remaining risk may result
from a combination of multiple common variants, each
conferring a small effect on breast cancer risk, with oddsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the polygenic model, a large number of low-penetrance
variants may have cumulative effect on both the overall
risk of disease [9] and an early disease onset [10,11].
A number of common single-nucleotide polymorphisms
(SNPs) associated with slightly modified risk of different
cancers have been identified through genome-wide associ-
ation studies (GWAS). By far, at least 22 GWAS were con-
ducted for breast cancer on different populations revealing
over 36 susceptibility loci [12]. Fifteen of them were con-
sistently confirmed in other GWAS or large replication
studies and meta-analyses [11,13-24].
Conducting analyses on different populations increases
the chance for generalization of conclusions and identifi-
cation of causal variants [25]. For its apparently high
level of genetic homogeneity [26,27], the Polish popula-
tion seems to be relevant for determining risk variants
with relatively small, although significant, effect on can-
cer prevalence. In this study we focus on verification of
selected associations with breast cancer risk among
Polish women. Eleven SNPs were chosen for replication
as commonly reported in different studies. Additional
five variants were selected for evaluation based on data
provided by Genetic Counseling of Cancer Center-
Institute of Oncology in Warsaw as frequently observed
in patients treated in Cancer Center. To our knowledge,
by now only two of these SNPs were investigated for asso-
ciation with breast cancer susceptibility in Poland.Methods
Studied population
The study was conducted at the Cancer Center-Institute
of Oncology in Warsaw and blood samples were col-
lected between 2003–2010. In total, 3212 women were
included: 1424 with newly-diagnosed breast cancer (992
of less than 50 years of age at diagnosis) and 1788
healthy individuals. The personal and familial cancer his-
tory was acquired by comprehensive interviews for all
patients. Cases representing families with at least one
breast or ovarian cancer diagnosis in a first- or second-
degree relative were considered as familial breast cancer.
Patients with less than 50 years of age at the moment of
diagnosis were considered as early-onset cases. The de-
tailed study groups statistics are presented in Table 1.Table 1 Group statistics of study cohorts
High risk mutation carriers*
Familial BCa (with family history) 168
Sporadic BCa (without family history) 75
All BCa cases 243
Controls -
* Women with any of BRCA1 mutations presented in Table 2. None of patients carriAll patients were tested for selected pathogenic muta-
tions in BRCA1 and BRCA2 chosen as the most frequently
occurred among Polish women with breast cancer [26,28].
For BRCA1, the whole sequence of exons 2, 5 and 20, and
a part of exon 11 (nucleotides 2893 to 3502 from the be-
ginning of this exon) were analyzed. The sequences of
primers used for amplification of relevant fragments are
listed in Additional file 1: Table S1. All identified mutations
are presented in Table 2; women with at least one of these
mutations were further considered as high-risk mutation
carriers. For BRCA2, selected 11 mutations (G1408T,
5467insT, 6174delT, 6192delAT, 6675delTA, 8138del5,
9152delT, 9182-2A>G, 9326insA, C9610T, 9631delC) were
directly sequenced and none of included patients carried
any of these mutations. Healthy women were recruited pri-
marily from the National Colorectal Cancer Screening Pro-
gram, which enrolls healthy persons from the general
population aged 50 years and older. All women exhibited
no known history of cancer and normal results of mam-
mography and screening colonoscopy. All patients and
control subjects were Polish Caucasians recruited from
two urban populations, Warsaw and Szczecin. The study
was approved by the local ethics committee (Medical
Center for Postgraduate Education and Cancer Center-
Institute of Oncology, Warsaw, Poland) and all participants
provided written informed consent. The study protocol
conforms to the ethical guidelines of the 1975 Declaration
of Helsinki.SNP selection
Sixteen SNPs were selected for replication among Polish
women (Table 3); 11 SNPs were chosen from the litera-
ture as consistently shown to be associated with breast
cancer risk in various studies (8 SNPs from GWAS and
3 from candidate gene studies) [8,29-35]. Additional five
SNPs were selected based on data provided by Genetic
Counseling of Cancer Center-Institute of Oncology in
Warsaw, Poland, as relatively frequent among coming
forward patients. All five are missense variants in three
genes: BRCA2 (3 SNPs), PALB2 and CDKN2A. One of
these SNPs (rs1799944 in BRCA2) was previously re-
ported to be associated with breast cancer in Cyprus
[36]. For rs3731249 in CDKN2A, contribution to early
onset breast cancer in Poland was suggested [37].No BRCA1/2 mutation carriers Total Median age
617 785 43 (29–65)
564 639 45 (17–62)
1181 1424 44 (17–65)
- 1788 58 (26–79)
ed any of selected BRCA2 mutations.
Table 2 Mutations detected in the selected regions of
BRCA1 gene among study participants
Exon 2 Exon 5 Exon 11 – part* Exon 20





*Nucleotides 2893 to 3502 from the beginning of the exon 11 of BRCA1 gene.
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association with breast cancer risk among Polish
women.
Genotyping
Genomic DNA was extracted from whole blood treated
with EDTA using the QIAamp DNA mini Kit (Qiagen,
Gernamy), following the manufacturer’s protocol. DNA
samples quantity and quality were evaluated using a
NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific Inc., USA). The samples which passed quality
control were adjusted to a final concentration of 50 ng/
μl in Tris–EDTA buffer (pH = 8), with concentrations of
Tris and EDTA not exceeding limits of 10 and 0.1 mM,
respectively. Individual genotyping was performed using
TaqMan SNP Genotyping Assays (Life Technologies,
USA), SensiMix™ II Probe Kit (Bioline Ltd, United
Kingdom) and a 7900HT Real-Time PCR system (Life
Technologies, USA) in 384-well format.Table 3 SNPs selected for analysis

















a/NCBI ID of genes localized in proximity to the SNPs of interest (source: HapMap).
b/SNP rs17468277 is in strong LD (r2 = 1) with rs1045485 in CASP8 (D302H).
c/SNP selected based on the date provided by Genetic Counseling of Cancer CenterStatistical analyses
Quality control of TaqMan genotyping results included:
thresholds for maximum individual missingness for each
of the SNPs < 0.05, maximum genotype missingness for
each of the individuals < 0.05 and the Hardy-Weinberg
disequilibrium < 0.001 for the control group. Associations
were examined using allelic chi2-test implemented
in PLINK v1.07 software (http://pngu.mgh.harvard.edu/
purcell/plink/). Furthermore, the Cochran-Armitage trend
test was performed using R software (http://www.r-pro-
ject.org/), "coin" library. OR 95% confidence interval (CI)
was estimated by normal approximation implemented in
"epitools" package. The Bonferroni correction was used
for multiple comparisons and p-valuecor < 0.05 was con-
sidered significant. The study sample size calculations
were conducted with tools supported in "pwr" library, as-
suming equal sizes of groups and baseline allele frequency
equal to frequency observed in control group. Calcula-
tions were performed for power equal 0.8 and significance
threshold equal 0.05. Results of sample size calculations
are presented in Additional file 2: Table S2.
Results
The vast majority of 1424 women with breast cancer
included in this study were non high-risk BRCA1 or
BRCA2 mutation carriers: only 243 (17.1%) patients
had one of BRCA1 mutations indicated in Table 2
and none of them had any of 11 genotyped mutations
in BRCA2. The number of patients with family cancer
history was similar to the number of sporadic tumorGenea Reference










BRCA2 (missense; N289H) CO-I
BRCA2 (missense; N991D) [36], CO-I
BRCA2 (missense; T598A) CO-I
TOX3/LOC643714 (between) [8,32,33]
MMP2 (promoter) [29]
PALB2 (missense; Q559R) CO-I
and Institute of Oncology (CO-I) in Warsaw.
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age at diagnosis was 44, ranging from 17 to 85.
The differences (p-value ≤ 0.0314) were observed for
seven out of 16 SNPs when allele frequencies between
all cases and control subjects were assessed with theTable 4 The significant SNP associations with breast cancer c
dbSNP
IDa
Region Geneb MA G1 vs G2 O
rs10941679 5p12 0.24 C vs N 1.
C noMut vs N 1.
S vs N 1.
S noMut vs N 1.
rs2736098 5p15.33 TERT 0.36 C vs N 0.
C noMut vs N 0.
C with Mut vs N 0.
F vs N 0.
F noMut vs N 0.
S vs N 0.
S noMut vs N 0.
rs13281615 8q24.21 0.45 C vs N 1.
C noMut vs N 1.
F vs N 1.
F noMut vs N 1.
S vs N 1.
S noMut vs N 1.
rs1219648 10q26 FGFR2 0.41 C vs N 1.
C noMut vs N 1.
F vs N 1.
F noMut vs N 1.
S vs N 1.
S noMut vs N 1.
rs2981582 10q26 FGFR2 0.41 C vs N 1.
C noMut vs N 1.
F vs N 1.
F noMut vs N 1.
S vs N 1.
S noMut vs N 1.
rs3817198 11p15.5 LSP1 0.34 F vs N 1.
F noMut vs N 1.
rs3803662 16q12.1 TOX3 0.30 C vs N 1.
C noMut vs N 1.
F noMut vs N 1.
S noMut vs N 1.
Bold denotes significant association after multiple testing adjustment (p-valuecor <
minor allele (+) strand frequency, OR; odds ratio, CI; confidence interval, N; control,
carriers.
a/SNP identifier based on NCBI SNP database;
b/NCBI ID of genes localized in proximity to the SNPs of interest (source: HapMap).chi2-test and four of them (rs2736098, rs13281615,
rs1219648, rs2981582) remained significantly associated
after multiple testing adjustment (p-valuecor ≤ 0.0197)
(Table 4 and Additional file 3: Table S3 for all results). The
same four SNPs show significant association (p-valuecor ≤onsidering allelic and Cochran-Armitage trend tests
R (95% CI) Allelic Cochran-Armitage
p-value p-valuecor p-value p-valuecor
14 (1.01-1.28) 2.97E-02 4.75E-01 2.71E-02 4.34E-01
15 (1.02-1.30) 2.29E-02 3.66E-01 2.04E-02 3.27E-01
17 (1.01-1.35) 4.25E-02 6.80E-01 3.94E-02 6.31E-01
20 (1.03-1.40) 2.06E-02 3.29E-01 1.87E-02 2.99E-01
77 (0.68-0.88) 5.81E-05 9.30E-04 5.51E-05 8.82E-04
78 (0.69-0.89) 2.37E-04 3.78E-03 2.25E-04 3.60E-03
74 (0.57-0.94) 1.70E-02 2.73E-01 1.55E-02 2.48E-01
81 (0.69-0.93) 4.68E-03 7.49E-02 4.56E-03 7.30E-02
80 (0.68-0.94) 8.63E-03 1.38E-01 8.25E-03 1.32E-01
74 (0.63-0.87) 2.61E-04 4.17E-03 2.38E-04 3.80E-03
76 (0.64-0.90) 1.46E-03 2.34E-02 1.36E-03 2.18E-02
19 (1.07-1.32) 1.23E-03 1.97E-02 1.17E-03 1.88E-02
21 (1.08-1.35) 7.23E-04 1.16E-02 6.77E-04 1.08E-02
20 (1.06-1.35) 5.19E-03 8.31E-02 5.24E-03 8.39E-02
22 (1.06-1.39) 4.60E-03 7.36E-02 4.53E-03 7.25E-02
18 (1.03-1.35) 1.61E-02 2.57E-01 1.42E-02 2.27E-01
20 (1.04-1.38) 1.09E-02 1.74E-01 9.61E-03 1.54E-01
30 (1.17-1.45) 1.01E-06 1.62E-05 1.13E-06 1.81E-05
36 (1.22-1.52) 7.20E-08 1.15E-06 7.95E-08 1.27E-06
26 (1.11-1.43) 4.21E-04 6.73E-03 3.76E-04 6.01E-03
33 (1.16-1.53) 4.02E-05 6.43E-04 3.24E-05 5.18E-04
36 (1.19-1.56) 7.32E-06 1.17E-04 8.53E-06 1.36E-04
39 (1.20-1.59) 5.58E-06 8.92E-05 6.76E-06 1.08E-04
31 (1.17-1.45) 9.10E-07 1.46E-05 1.17E-06 1.88E-05
35 (1.21-1.51) 1.20E-07 1.91E-06 1.54E-07 2.46E-06
26 (1.11-1.43) 4.05E-04 6.48E-03 4.09E-04 6.54E-03
32 (1.15-1.51) 6.49E-05 1.04E-03 6.11E-05 9.77E-04
37 (1.19-1.56) 5.70E-06 9.12E-05 7.67E-06 1.23E-04
38 (1.20-1.59) 5.69E-06 9.11E-05 7.97E-06 1.27E-04
16 (1.02-1.32) 2.45E-02 3.92E-01 2.36E-02 3.78E-01
16 (1.00-1.33) 4.46E-02 7.14E-01 4.34E-02 6.94E-01
13 (1.01-1.27) 3.14E-02 5.02E-01 3.22E-02 5.15E-01
16 (1.03-1.31) 1.30E-02 2.08E-01 1.35E-02 2.16E-01
16 (1.00-1.34) 4.45E-02 7.11E-01 4.53E-02 7.25E-01
16 (1.00-1.35) 4.75E-02 7.61E-01 4.82E-02 7.71E-01
0.05). G1 vs. G2; compared groups of cases and controls, respectively, MA;
C; cancer (all cases), F; familial cancer, S; sporadic cancer, noMut; non-mutation
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tients tested negative for the high-risk mutations. The
strongest association was observed for rs1219648 and
rs2981582 (p-valuecor of 1.62E-05 and 1.46E-05, respect-
ively). Both are located in intron 2 of FGFR2 encoding the
fibroblast growth factor receptor 2 protein. The minor al-
lele of rs2736098 located in TERT gene was associated
(p-valuecor of 9.30E-04) with a decreased risk of breast can-
cer. Fourth SNP (rs13281615) was located in 8q24 locus,
known as multicancer susceptibility region [38]. None of
the 16 SNPs showed association after Bonferroni correc-
tion in the group of BRCA1 mutation carriers.
SNPs rs2981582 and rs766173 are in the same linkage
disequilibrium (LD) blocks with rs1219648 (r2 = 0,967)
and rs1799944 (r2 = 1), respectively [39]. Consistent with
expectations, both pairs indicate similar associations.
To further explore associations with breast cancer, we
performed analyses separately in groups of familial and
sporadic cases, with additional stratification based on
mutations in high-risk genes. Two SNPs in FGFR2 show
significant association with both familial and sporadic
cases (p-valuecor ≤ 6.73E-03) (Table 4). Additionally,
rs2736098 (TERT) was associated with sporadic cancers
only (p-valuecor ≤ 0.0234). Results for both types of
breast cancer did not change when carriers of high-risk
mutation were excluded. All significant associations ob-
tained in the chi2-test were confirmed by the Cochran-
Armitage trend test analysis (Table 4).
Discussion
Several association studies support the polygenic inherit-
ance model of breast cancer, showing increasing risk of
disease when many predisposition variants of low effect
size were combined [11,40]. However, strong bias of the
association results, by highly penetrant genetic determi-
nants, such as deleterious mutation in BRCA1 or BRCA2
gene, should be taken into account. Also, significant
modification of breast cancer risk in BRCA1/2 mutation
carriers was observed in association with selected low-
penetrant risk alleles [41].
In this replication study, association of selected sus-
ceptibility SNPs with both familial and sporadic breast
cancers was analyzed. Among studied patients, at least
one from nine different BRCA1 mutations was shown in
over 11% of sporadic cases and 21% of familial cancers,
which is in agreement with previous findings for women
in Poland [28].
From 16 susceptibility variants selected for analysis,
four SNPs, representing three different loci, significantly
associated (p-valuecor < 0.05) with breast cancer risk,
both in group of all cases as in sporadic and familial can-
cer subgroups, and after exclusion of BRCA1 mutation
carriers (Table 4). Two SNPs (rs1219648 and rs2981582)
lie within intron 2 of FGFR2 gene, encoding a receptortyrosine kinase which participates in activation of signal-
ing pathways engaged in tumor induction and progres-
sion [42] and mediates breast cancer cell proliferation
through D-type cyclins [43]. Amplification or overex-
pression of FGFR2 was observed in 5-10% of breast tu-
mors [44] and breast cancer cell lines [45].
The association of FGFR2 variants with breast cancer
risk was reported in several studies and is very well doc-
umented, with the strongest association observed for
rs2981582 [8,30]. Minor allele of rs2981582 was found
to correlate with positive family history of breast cancer
[46-48] and early-onset of non-familial breast cancer
[47]. Data provided by The Consortium of Investigators
of Modifiers of BRCA1/2 (CIMBA) indicated that the
FGFR2 locus associated with breast cancer in BRCA2
mutation carriers but not in BRCA1 mutation carriers
[49,50]. This finding may reflect the differences in the
distribution of tumor subtype. Rs2981582 is consistently
most strongly associated with the estrogen receptor
(ER)-positive/low grade tumors [23], which are more
typical for BRCA2 mutation carriers and general popula-
tion not selected for carrier status [51]. Consistently, our
findings indicated higher OR and stronger association of
both FGFR2 variants in groups of patients without
BRCA1 mutations (Table 4). Possible correlation of
FGFR2 risk alleles with gene expression was suggested,
as intron 2 contains several putative transcription-factor
binding sites [52]. However, relationship of risk allele
rs2981582 with increased expression of FGFR2 has not
been clarified yet [52,53].
SNP rs13281615 is located in a ‘gene desert’ on
chromosome 8q24, where five independent cancer sus-
ceptibility loci were identified so far [54]. One loci,
termed ‘region 2’ (stretched from 128.35-128.51 Mb),
is specific for breast cancer only and tagged by
rs13281615 [38]. Gene desert at 8q24 is located few
hundred kilo bases telomeric to the proto-oncogene
Myc. As multiple enhancer elements were identified in
this region, it was suggested that they can regulate the
transcription of Myc. One such element was shown to
physically interact with Myc promoter via Tcf-4 tran-
scription factor binding and this interaction affected
c-Myc expression in an allele specific manner [55].
Overexpression of c-Myc was observed in breast can-
cer tissue [56]; its reduction inhibited breast tumor
cells growth [57]. In agreement with our findings,
SNP rs13281615 was associated with increased risk of
breast cancer among people at higher risk (who have
positive family cancer history or BRCA1/BRCA2 muta-
tion) [17,48]. It was also shown that the association of
rs13281615 was stronger for ER-positive disease, with
no evidence of an association for ER-negative disease
[58], although, no association with either BRCA1 or
BRCA2 carriers was observed [19].
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with cancer risk at different locations was reported,
especially for lung and bladder cancers [59-61]. For
breast cancer, the reported findings have been contro-
versial [31,60,62]. Haiman et al. [62] observed positive
association of 5p15 locus with increased risk of breast
cancer. In turn, Savage et al. [31] suggested protective
effect of three correlated SNPs in this region, including
rs2736098, among Polish women with positive family his-
tory. Similarly, in our study, rs2736098 minor allele was
associated with reduced overall and sporadic breast cancer
risk. For familial cancers, association was also observed,
although not statistically significant after Bonferroni
adjustment.
Rs2736098 is located in coding sequence of TERT gene,
therefore it has been considered as a putative cancer sus-
ceptibility gene. TERT encodes the catalytic subunit of
telomerase, which is crucial in cellular proliferation be-
cause counteracts telomere-dependent replicative aging
[63]. In many types of cancer, TERT shows a high-level of
expression, which possibly induces excessive cell growth
and carcinogenesis [64]. Although rs2736098 is a syn-
onymous polymorphism, it has been shown to be corre-
lated with telomere length, however not with TERT
expression [59]. On the other hand, rs2853669, which is
in LD with rs2736098 (r2 = 0.79), was shown to be in-
volved in allele specific regulation of telomerase activity
in non-small cell lung cancer [65]. Therefore, rs2736098
might be just a tagging SNP of causal variant.
To our knowledge, this is the first such comprehensive
study examining association of several potential low-
penetrance breast cancer susceptibility loci among women
in Poland. Beside rs2736098 in TERT, only the association
of rs3731249 in CDKN2A was analyzed previously and
significant correlation was identified for early-onset breast
cancers [37]. Our study do not confirm this association in
any of analyzed models. One of possible explanations of
this discrepancy is that more invasive and aggressive types
of cancers might have been included in previous study.
Also, correction of significance for multiple testing was
not conducted in that study, comparing with ours. How-
ever, lack of this SNP association, similarly like in case of
studied BRCA1 variants, could be also explained by insuf-
ficient study sample size to detect such association
(Additional file 2: Table S2) or SNP effect size lower than
expected. The rs2736098 in TERT locus shows protective
effect in both studies and it seems to be specific for the
Polish women, indicating the benefit of studying small,
homogenous populations for low-penetrance risk variants
associations.
Conclusions
We confirmed the association of four SNPs representing
three previously reported susceptibility loci with breastcancer risk among Polish women: FGFR2 (rs1219648 and
rs2981582), TERT (rs2736098) and 8q24 (rs13281615).
Noteworthy is that the minor allele of rs2736098, the
synonymous polymorphism in TERT gene, was associated
with a decreased risk of overall breast cancer, which by
now was observed only among women in Poland. Due to
the population differences in allele frequencies, identifi-
cation of general genetic risk factors requires sets of asso-
ciation studies conducted on different populations. Our
study confirmed some benefits of studying small and
homogenous populations.
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Additional file 2: Table S2. The calculation of sample size necessary for
given effect detection with study power equal 0.8.
Additional file 3: Table S3. SNP associations according to allele
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